

B<sup>1</sup>  
collateral extent, and by decreased target area delayed arrival extent. By way of summary, at 1, 2 and 6 months, the target wall thickening increased relative to baseline at 4.4%, 6.3% and 7.7%, respectively; the target wall motion increased relative to baseline at 2.7%, 4.4% and 6.4%, respectively; the target area collateral extent increased relative to baseline at 8.3%, 10.9% and 11.2%, respectively; and the target area delayed arrival extent decreased relative to baseline at -10.0%, -8.3% and -10.0%, respectively.

Please amend the paragraph, beginning on page 34, line 11, to read as follows:

B<sup>2</sup>  
The fourth SAQ scale to be evaluated was "treatment satisfaction." The data summarizing treatment satisfaction is presented in Table 5 herein.

Please amend the paragraph, beginning on page 41, line 1, to read as follows:

The mean pharmacokinetic parameters for rFGF-2 in humans as a function of dosage and mode of administration are summarized in Table 7 herein. Referring to Table 7, the  $T_{1/2}$  for FGF-2 in humans was determined to range from  $2.2 \pm 3.7$  hours at low dose ( $0.33\text{--}2.0 \mu\text{g/kg}$ ) IC to  $7.0 \pm 3.5$  hours at a dose of  $18\text{--}36 \mu\text{g/kg}$  IV; given the limitations of the assay, the terminal half-life is estimated at 5-7 hours for all groups. The clearances of FGF-2 ranged from 13.2 to 18.2 L/hour/70 kg man. Finally, the steady state volume ( $V_{ss}$ ) was determined to range from  $11.3 \pm 10.4$  L/70 kg man to  $16.8 \pm 10.7$  L/70 kg man.

B<sup>3</sup> [ Please amend the Table on page 41 to read as follows: ]

Table 7. Mean rFGF-2 PK Parameters in Humans

<i>FGF-2 Dose <math>\mu\text{g/kg}</math></i>	<i>N</i>	<i>Route</i>	<i>CL (L/hr/70kg)</i>	<i>t<sub>1/2</sub> (h)</i>	<i>V<sub>ss</sub> (L/70kg)</i>
0.3 - 2	16	IC	18.2 $\pm$ 13.4	2.2 $\pm$ 3.7	11.3 $\pm$ 10.4
6 - 12	8	IC	13.2 $\pm$ 7.3	3.1 $\pm$ 2.5	12.1 $\pm$ 4.9
24 - 48	28	IC	14.7 $\pm$ 8.3	6.3 $\pm$ 1.8	16.8 $\pm$ 10.7
18 - 36	14	IV	13.9 $\pm$ 7.9	7.0 $\pm$ 3.5	16.4 $\pm$ 8.6

~~Please amend the specification to delete Example 4, on page 51.~~

~~Please amend the title for Example 5, on page 51, to read as follows:~~

**EXAMPLE 4**

**“Unit Dose and Pharmaceutical Composition of rFGF-2 for  
the Phase II Human Clinical Trial”**

~~Please amend the title for Example 6, on page 52, to read as follows:~~

**EXAMPLE 5**

**“Unit Dose and Pharmaceutical Composition of rFGF-2 for  
the Phase II Human Clinical Trial”**

~~Please amend the paragraph beginning on page 61, line 10, to read as follows:~~

~~Table 8 summarizes demographic features of the subjects enrolled in the trial. These  
features were similar among the four treatment groups (Table 8).~~

~~Please amend the title for Table 7 on page 61 to read as follows:~~

**Table 8 Summary of Demography**

**REMARKS**

Status of the Claims

Claims 35-49 have been rejected. Claims 50-52 are objected to. Claims 35-52 remain pending in the application. The Examiner's remarks in the Office Action are addressed below in the order set forth therein.

Corrections to the Specification

The specification has been amended to correct for obvious typographical errors. In particular, the specification made reference to a Table 7 on page 9, line 9, though no Table 7